Aptevo Therapeutics Files 8-K
Ticker: APVO · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1671584
| Field | Detail |
|---|---|
| Company | Aptevo Therapeutics Inc. (APVO) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-statements, exhibits, sec-filing
Related Tickers: APVO
TL;DR
APVO filed an 8-K with financial statements and exhibits on Dec 9, 2025.
AI Summary
Aptevo Therapeutics Inc. filed an 8-K on December 9, 2025, reporting financial statements and exhibits. The company, incorporated in Delaware with its principal executive offices in Seattle, Washington, operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing indicates that Aptevo Therapeutics Inc. has submitted required financial statements and exhibits to the SEC, providing an update on its corporate and financial status.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate material changes or events.
Key Numbers
- 001-37746 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1567056 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Aptevo Therapeutics Inc. (company) — Registrant
- 20251209 (date) — Filing Date
- 2834 (number) — Standard Industrial Classification (Pharmaceutical Preparations)
- 206-838-0500 (phone_number) — Business Phone
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits as of December 9, 2025.
What is Aptevo Therapeutics Inc.'s Standard Industrial Classification code?
Aptevo Therapeutics Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on December 09, 2025.
Where are Aptevo Therapeutics Inc.'s principal executive offices located?
Aptevo Therapeutics Inc.'s principal executive offices are located at 2401 4th Avenue, Suite 1050, Seattle, Washington, 98121.
What is the company's SEC file number?
The company's SEC file number is 001-37746.
Filing Stats: 478 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2025-12-09 17:23:00
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value APVO The Nasdaq Stock Mar
Filing Documents
- apvo-20251209.htm (8-K) — 44KB
- apvo-ex99_1.htm (EX-99.1) — 35KB
- img237228349_0.jpg (GRAPHIC) — 14KB
- 0001193125-25-312972.txt ( ) — 210KB
- apvo-20251209.xsd (EX-101.SCH) — 24KB
- apvo-20251209_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On December 9, 2025, Aptevo Therapeutics Inc. (the "Company") issued a press release announcing compelling safety and strong remission rates for mipletamig in frontline acute myeloid leukemia (AML) at American Society of Hematology (ASH) 2025. Across dose-optimization Cohorts 1-3 of its Phase 1b/2 RAINIER trial, mipletamig combined with AZA/VEN demonstrated high remission rates and a compelling safety/tolerability profile, for newly diagnosed patients with AML unfit for intensive chemotherapy. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Description 99.1 Press release of Aptevo Therapeutics Inc. dated December 9, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. APTEVO THERAPEUTICS INC. Date: December 9, 2025 By: /s/ Marvin L. White Marvin L. White President and Chief Executive Officer